OMT-28 is under clinical development by OMEICOS Therapeutics and currently in Phase II for Mitochondrial Myopathy. According to GlobalData, Phase II drugs for Mitochondrial Myopathy does not have sufficient historical data to build an indication benchmark PTSR for Phase II. GlobalData uses proprietary data and analytics to create drugs-specific PTSR and LoA in the OMT-28 LoA Report. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
OMT-28 overview
OMEICOS Therapeutics overview
OMEICOS Therapeutics (OMEICOS) is a biopharmaceutical company. It develops small molecule therapeutics for the prevention and treatment of cardiovascular and ophthalmic diseases. It utilizes its proprietary technology of the body’s own omega-3 fatty acid metabolic processes to develop therapeutics. Its clinical product portfolio includes OMT-28, OMT 174 and OMT-224. OMT-28 is a synthetic small molecule analog of the omega-3 fatty acid metabolite 17, 18-EEQ which is developed for the treatment of paroxysmal and persistent atrial fibrillation, ventricular arrhythmia, myocardial infarction, macular edema diseases, and kidney injury. The company also conducts research and development. OMEICOS is headquartered in Berlin, Germany.
For a complete picture of OMT-28’s drug-specific PTSR and LoA scores, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.